STAT
APRIL 23, 2025
To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as GLP-1s. District Court for the Northern District of California. Continue to STAT+ to read the full story…
STAT
DECEMBER 4, 2024
Also, compounding pharmacies fire back at Novo Nordisk for its assertion that GLP-1 drugs are too difficult to compound. Lots today on GLP-1s: First we see tirzepatide outperforming semaglutide in a head-to-head study in obesity. Also, a Michael Gilman company pivots and more. Read the rest…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 19, 2024
The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Businesses are changing prescriptions, mixing in additives, or encouraging stockpiling of existing compounded products. Some have disappeared altogether.
STAT
MAY 7, 2025
The move means that patients will no longer have access to cheaper versions from compounding pharmacies. Due to ongoing shortages of the Lilly drugs, compounding pharmacies were permitted to make copies that sold for substantially less.
STAT
APRIL 25, 2025
Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies are legally allowed to make versions of branded treatments if the drugs are deemed to be in shortage by the FDA.
STAT
OCTOBER 30, 2024
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA’s shortage list. Continue to STAT+ to read the full story…
Expert insights. Personalized for you.
324 
Let's personalize your content